Eli Lilly is the stock that burst Novo Nordisk’s GLP-1 bubble.
Having strongly rewarded investors who believed in that disruption, Eli Lilly now faces a tricky period of diminishing pricing power and a demanding valuation that assumes no missteps in the defense of market share. Is this phase of the GLP-1 story still attractive?
